BIOCHINA

News

Vivo Capital Leads Over RMB 1 Billion Financing for China Radiopharma Biotech Full-Life Technologies

Details

7% Surge! Hengrui Pharma and BMS Announce $15.2B Global Strategic Collaboration

Details

China Biopharma BD & M&A Monthly Review | April 2026 (32 Deals)

Details

Innovent Biologics Reports Q1 2026 Product Revenue Above RMB 3.8 Billion, Up Over 50% YoY

Details

China CAR-T Milestone: Huadao Biopharma Files First Marketing Application for RMB 200K-Class CD19 Cell Therapy with Fully Automated Manufacturing Push

Details

RMB 500M Shanghai CGT Industry Fund (Heyuan Hongsheng CGT Industry Fund) Officially Launched

Details

BeOne Enters Up to $2.0B Global Option, License & Collaboration Agreement for PD-1/VEGF/CTLA-4 Trispecific Antibody HH160

Details

15 January 2026

Stop Watching the Market. Take a Seat at the Table – China & Russia Session at BIOCHINA 2026

Details

15 January 2026

BIOCHINA 2026 Surpasses 10,000 Registrations ！

Details

12 January 2026

2025: A Breakout Year for China’s Innovative Drug Industry

Details

1 2 3 Next